Modeling study evaluates clinical outcomes of vedolizumab positioning in moderate to severe Crohn's disease, highlighting strategies to optimize biologic sequencing.
Several biologics are available for the treatment of moderate to severe Crohn's disease, but data to optimize their use are scarce. Vedolizumab (VDZ) is a gut-selective anti-lymphocyte trafficking monoclonal antibody that was approved in 2014 for the treatment of moderate to severe Crohn's disease. Based on real-world evidence, a model was developed to examine the effect of VDZ's position in the treatment sequence on clinical outcomes.
No takes yet. Share an insight, caveat, or question.
Louis et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: